(NASDAQ: ELTX) Elicio Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.13%.
Elicio Therapeutics's earnings in 2026 is -$35,737,000.On average, 6 Wall Street analysts forecast ELTX's earnings for 2026 to be -$55,629,359, with the lowest ELTX earnings forecast at -$58,256,269, and the highest ELTX earnings forecast at -$54,392,333. On average, 6 Wall Street analysts forecast ELTX's earnings for 2027 to be -$46,947,533, with the lowest ELTX earnings forecast at -$76,120,959, and the highest ELTX earnings forecast at -$32,694,845.
In 2028, ELTX is forecast to generate -$47,641,060 in earnings, with the lowest earnings forecast at -$58,256,269 and the highest earnings forecast at -$35,667,104.